Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is expected to grow by 2034
DelveInsight's"Myelodysplastic Syndrome Market Insight, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of the Myelodysplastic Syndrome historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock key insights into the Myelodysplastic Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Myelodysplastic Syndrome Market Size
Key Takeaways from the Myelodysplastic Syndrome Market Report
In January 2025:- Keros Therapeutics Inc.:- This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk MDS, or more recently defined as myelodysplastic neoplasms, with or without ring sideroblasts. The study is divided into the Screening Period, Double-blind Treatment Period, Safety Follow-Up Period and Long-term Follow-up Period.
In January 2025:- Bristol-Myers Squibb- The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
In the 7MM, the US accounted for the highest Myelodysplastic Syndrome incident cases in 2023, with around 21,000 cases; these numbers are expected to increase during the forecast period.
Among the age-specific cases, the cases from the age group 80+ accounted for the highest incident cases in 2023 in the US, with nearly 40% of total cases.
Among the subtype-specific cases, RAEB/MDS-EB accounted for the highest number in the US in 2023.
Amongst EU4 and the UK, Germany accounted for the highest incident cases, followed by France, while Spain occupied the bottom of the ladder in 2023.
The leading Myelodysplastic Syndrome Companies such as Bristol-Myers Squibb, Astex Pharmaceutical, Taiho Oncology, Fibrogen, AbbVie, Gilead Sciences, Novartis, Syros Pharmaceuticals, Takeda, Pfizer, Geron Corporation, Karyopharm Therapeutics, Antengene Corporation, BerGenBio ASA, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac and others.
Promising Myelodysplastic Syndrome Therapies such as Deferasirox, Tebapivat, KER-050, Luspatercept, Epoetin Alfa, and others.
Stay ahead in the competitive landscape of the Myelodysplastic Syndrome Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Myelodysplastic Syndrome Treatment Market Size
Myelodysplastic Syndrome Epidemiology Segmentation in the 7MM
Total Incident Population of Myelodysplastic Syndrome
Age-specific Incident Population of Myelodysplastic Syndrome
Subtype-specific Incident Population of Myelodysplastic Syndrome
Risk-specific Incident Population of Myelodysplastic Syndrome
Mutation-specific Incident Population of Myelodysplastic Syndrome
Download the report to understand which factors are driving Myelodysplastic Syndrome epidemiology trends @ Myelodysplastic Syndrome Prevalence
Myelodysplastic Syndrome Marketed Drugs
VIDAZA (azacitidine): Bristol Myers Squibb
VIDAZA is a pyrimidine nucleoside analog of cytidine. VIDAZA is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of azacitidine required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. It was first approved by the US FDA in May 2004 for the Myelodysplastic Syndrome treatment.
DACOGEN (decitabine): Johnson & Johnson
DACOGEN is a nucleoside metabolic inhibitor indicated for the treatment of adult patients with myelodysplastic syndromes including previously treated and untreated, de novo and secondary MDS. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA. Non-proliferating cells are relatively insensitive to decitabine. It was first approved by the US FDA in May 2006.
Myelodysplastic Syndrome Emerging Drugs
Venetoclax: Abbvie
Venetoclax by Abbvie is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 (BCL-2) protein. Currently, the drug is being investigated in a Phase III trial to treat adult patients with newly diagnosed higher-risk Myelodysplastic Syndrome. Moreover, in July 2021, the combination was granted Breakthrough Therapy Designation in higher risk Myelodysplastic Syndrome.
Tamibarotene: Syros Pharmaceuticals
Tamibarotene is an oral selective retinoic acid receptor alpha (RARA) agonist being developed for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. Approximately 50% of Myelodysplastic Syndrome patients and 30% of AML patients have RARA overexpression. When RARA is expressed more than its tightly controlled natural ligand, cells in the bone marrow may not differentiate into healthy myeloid cells, which can lead to hematological malignancies. However, when oral tamibarotene is administered, tamibarotene binds to RARα, allowing for the restoration of gene expression and myeloid differentiation. It is currently being investigated in the Phase III SELECT-MDS-1 trial in newly diagnosed higher-risk myelodysplastic syndrome patients with RARA overexpression.
Discover the future of Myelodysplastic Syndrome Treatments with DelveInsight's latest market report. Get expert insights and forecasts—download now! @ Myelodysplastic Syndrome Market Drivers and Barriers
Myelodysplastic Syndrome Drugs Market Insights
There is a vast pipeline of targeted agents under pre-clinical and clinical development, potentially able to modify the natural history of the diverse disease spectrum of MDS. The B-cell leukemia/lymphoma-2 (BCL-2) inhibitor, venetoclax is to date one of the most potent anti-apoptotic inhibitors, representing a novel promising agent. This small molecule blocks the binding of BH3 proteins to BCL-2, allowing the activation of BCL2 Antagonist/Killer/BCL2 associated X on the surface of mitochondria leading to cell death of cancer cells because of the release of cytochrome C through a mitochondrial outer membrane permeabilization (MOMP) process. IDH1 and IDH2 inhibitors have also recently shown an acceptable ORR in different clinical trials. FLT3 inhibitors represent another important potential group of targeted compounds in MDS patients harboring FLT3 mutations.
Myelodysplastic Syndrome Market Outlook
While for more than a decade the therapeutic scenario of Myelodysplastic Syndrome syndromes has been dominated by very few available regimens associated with dismal results, especially for patients with higher-risk disease and who failed HMAs, in the last 2 years there was a flow of an incredible variety of new targeted agents and investigational approaches that possibly will reach the clinical setting in short time. If currently available therapies still include HMAs, lenalidomide, growth factor support, chemotherapy, and allo-HSCT, there is now the possibility to choose among new investigational treatments rationally designed to exert targeted actions and increase the response rates in categories of patients that so far remained precision drug-orphans.
Explore the dynamics of the Myelodysplastic Syndrome Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Myelodysplastic Syndrome Ongoing Clinical Trials Analysis
Scope of the Myelodysplastic Syndrome Market Report
Coverage- 7MM
Study Period- 2020-2034
Myelodysplastic Syndrome Companies- Bristol-Myers Squibb, Astex Pharmaceutical, Taiho Oncology, Fibrogen, AbbVie, Gilead Sciences, Novartis, Syros Pharmaceuticals, Takeda, Pfizer, Geron Corporation, Karyopharm Therapeutics, Antengene Corporation, BerGenBio ASA, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac and others.
Myelodysplastic Syndrome Therapies- Deferasirox, Tebapivat, KER-050, Luspatercept, Epoetin Alfa, and others.
Myelodysplastic Syndrome Therapeutic Assessment: Myelodysplastic Syndrome Current Marketed and Myelodysplastic Syndrome Emerging Therapies
Myelodysplastic Syndrome Market Dynamics: Myelodysplastic Syndrome market drivers and Myelodysplastic Syndrome market barriers
Myelodysplastic Syndrome Unmet Needs, KOL's views, Analyst's views, Myelodysplastic Syndrome Market Access and Reimbursement
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary of Myelodysplastic Syndrome (MDS)
4 Myelodysplastic Syndrome (MDS) Market Overview at a Glance
5 Key Events
6 Epidemiology and Market Forecast Methodology
7 Disease Background and Overview
8 Diagnostic Algorithm
9 British Society for Hematology guidelines for the Diagnosis and Evaluation of Prognosis of Adult MDS
10 Treatment
11 National Comprehensive Cancer Network recommendations for myelodysplastic syndrome
12 Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
13 JSH Practical Guidelines for MDS
14 British Society for Hematology Guidelines for the Management of Adult Myelodysplastic Syndromes
15 Treatment Algorithm
16 Epidemiology and Patient Population
17 Organizations contributing toward Myelodysplastic Syndrome
18 Patient Journey
19 Marketed Drugs
20 Emerging Therapies
21 Myelodysplastic Syndrome: Seven Major Market Analysis
22 Unmet Need
23 SWOT Analysis
24 KOL Views
25 Market Access and Reimbursement
26 Appendix
27 DelveInsight Capabilities
28 Disclaimer
29 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 919650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
9 hours ago
- Globe and Mail
Facial Lines Market Set for Significant Transformation by 2032, Forecasts DelveInsight
"Facial Lines Market" Facial Lines Companies working in the market are Ipsen, Evolus, Inc., and others. (Albany, USA) DelveInsight's ' Facial Lines - Market Insight, Epidemiology, And Market Forecast - 2032 ″ report offers an in-depth understanding of the Facial Lines, historical and forecasted epidemiology as well as the Facial Lines market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Facial Lines market is experiencing steady advancements, driven by evolving treatment approaches and research innovations. DelveInsight's latest 7MM report provides comprehensive insights into key epidemiology trends and market dynamics. Some of the key facts of the Facial Lines Market Report: According to DelveInsight, the market for Facial Lines in the 7MM is expected to grow steadily from 2019 to 2032. According to the Global Burden of Disease Study 2019, the global incidence of orofacial clefts decreased from 237,258 cases in 1990 to 192,708 cases in 2019, with an age-standardized rate (ASR) reduction from 3.61 per 100,000 in 1990 to 2.98 per 100,000 in 2019. Ultraviolet (UV) light and sunlight exposure significantly accelerate skin aging, resulting in photoaging, which is responsible for 90% of visible skin changes. The wrinkle scale, rated on a 0-9 scale, is a valuable tool in research for evaluating different types of aesthetic procedures. Emerging drugs for aesthetic treatments include IPN10200, PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, and others. Leading companies in the aesthetic and dermatology market include Ipsen, Evolus, Inc., and others. Photoaging continues to be a significant factor in skin damage, driving the development of new treatments in the aesthetics industry. To Know in detail about the Facial Lines market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Facial Lines Market Forecast Facial Lines Overview Facial lines, commonly known as wrinkles, are visible creases or folds in the skin that develop due to aging, repetitive facial expressions, sun exposure, and other environmental and genetic factors. These lines can appear on different areas of the face, including the forehead, around the eyes (crow's feet), between the eyebrows (glabellar lines), and around the mouth (nasolabial folds and marionette lines). The primary cause of facial lines is the gradual decline in collagen and elastin production, which leads to reduced skin elasticity and firmness. Additionally, repeated muscle movements, such as frowning, smiling, or squinting, contribute to the formation of dynamic wrinkles, which may become static over time as the skin loses its ability to bounce back. External factors such as prolonged sun exposure, smoking, pollution, and poor skincare habits can accelerate the development of facial lines. While facial lines are a natural part of aging, various treatment options are available to minimize their appearance. These include topical treatments (retinoids, peptides, and hyaluronic acid-based creams), minimally invasive procedures (botulinum toxin injections, dermal fillers, and laser therapy), and more advanced interventions like chemical peels, microneedling, and facelift surgery. With increasing consumer demand for aesthetic procedures and advancements in dermatological treatments, the market for facial line reduction continues to grow, offering both preventive and corrective solutions to individuals seeking youthful, smoother skin. Facial Lines Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Facial Lines Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facial Lines market or expected to be launched during the study period. The analysis covers the Facial Lines market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the activities of the facial lines pipeline development. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Facial Lines Market Strengths Growing consumer interest in non-invasive and minimally invasive cosmetic procedures, such as botulinum toxin injections and dermal fillers, is driving market expansion. Increasing social media influence and a focus on youthful appearances further fuel demand. Continuous improvements in anti-aging treatments, including next-generation fillers, laser therapies, and skincare formulations with peptides and hyaluronic acid, enhance treatment efficacy and patient satisfaction. Facial Lines Market Weaknesses Premium aesthetic procedures, such as laser resurfacing and high-end dermal fillers, can be expensive, limiting accessibility for a broader population, particularly in developing regions. Strict regulations on cosmetic injectables and emerging anti-aging treatments, along with concerns about side effects or complications, may hinder market growth and delay product approvals. Scope of the Facial Lines Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Facial Lines Therapies: IPN10200, PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, and others. Key Facial Lines Companies: Ipsen, Evolus, Inc., and others. Facial Lines Therapeutic Assessment: Facial Lines currently marketed and Facial Lines emerging therapies Facial Lines Market Dynamics: Facial Lines market drivers and Facial Lines market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Facial Lines Unmet Needs, KOL's views, Analyst's views, Facial Lines Market Access and Reimbursement To learn more about the key players and advancements in the Facial Lines Treatment Landscape, visit the Facial Lines Market Analysis Report Table of Contents 1. Facial Lines Market Report Introduction 2. Executive Summary for Facial Lines 3. SWOT analysis of Facial Lines 4. Facial Lines Patient Share (%) Overview at a Glance 5. Facial Lines Market Overview at a Glance 6. Facial Lines Disease Background and Overview 7. Facial Lines Epidemiology and Patient Population 8. Country-Specific Patient Population of Facial Lines 9. Facial Lines Current Treatment and Medical Practices 10. Facial Lines Unmet Needs 11. Facial Lines Emerging Therapies 12. Facial Lines Market Outlook 13. Country-Wise Facial Lines Market Analysis (2019–2032) 14. Facial Lines Market Access and Reimbursement of Therapies 15. Facial Lines Market Drivers 16. Facial Lines Market Barriers 17. Facial Lines Appendix 18. Facial Lines Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Toronto Star
a day ago
- Toronto Star
I'm about to have my first baby. How much maternity leave must my employer allow me? Ask Soma
Q: I am having my first child soon and I am worried about how much time I will get to stay home from work with my baby. What are my maternity leave entitlements? A: Congratulations! Becoming a first-time parent can be a nerve-racking experience. Here is what you need to know. The Employment Standards Act (ESA) states that pregnant employees in Ontario have a right to take up to 17 weeks of unpaid time off for pregnancy leave. ARTICLE CONTINUES BELOW Additionally, birth mothers who take pregnancy leave are also entitled to up to 61 weeks of unpaid parental leave once the child is born. The ESA also outlines that birth mothers who do not take pregnancy leave and all other new parents (including adoptive) are entitled to up to 63 weeks parental leave. However, in order to qualify for pregnancy or parental leave, an employee must have started employment in Ontario at least 13 weeks before their baby's due date. Business Opinion Soma Ray-Ellis: Is my employer allowed to monitor me in the workplace digitally and by video surveillance? Ask Soma When you're at work, your privacy is limited — your employer can monitor shared spaces and An employee is required to give their employer at least two weeks' written notice before beginning pregnancy leave. They must also provide a certificate from a medical practitioner (which can include a doctor, a midwife, or a nurse practitioner) stating the baby's due date if their employer requests it. While pregnancy and parental leave offered through the ESA are both unpaid, an employee may be entitled to paid benefits through the federal Employment Insurance (EI) program. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW EI maternity benefits are offered to biological mothers (or surrogates) who cannot work because they are pregnant or have recently given birth. The program provides a maximum of 15 weeks of EI maternity benefits. The 15 weeks can start as early as 12 weeks before the expected date of birth and can end as late as 17 weeks after the date of birth. There are also standard and extended parental leave benefits available through EI. EI legislation states that standard benefits can be paid for a maximum of 35 weeks and must be claimed within a 52-week period after the week the child was born or placed for the purpose of adoption. These benefits are available to any biological, adoptive, or legally recognized parents at a weekly benefit rate of 55% of the claimant's average weekly insurable earnings up to a maximum insurable amount of $65,700. The 35 weeks of standard parental benefits can be shared by two parents. The extended parental benefits are for a maximum of 61 weeks which must be used within a 78-week period (18 months). ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW To be eligible for EI maternity or parental benefits, you must be employed in insurable employment in Canada, your normal weekly earnings are reduced by more than 40%, and you have accumulated at least 600 hours of insurable employment in the 52 weeks before the start of your claim. Business Opinion Soma Ray-Ellis: Show me the money! How will Ontario's new wage transparency law affect me? Ask Soma Starting next year, writes Soma Ray-Ellis, new Ontario pay transparency laws will require every Keep in mind that your job security is legally protected while you are on leave, and an employer cannot penalize an employee for taking pregnancy/parental leave. In fact, the ESA outlines that employees on leave have the right to continue in certain benefit plans and earn seniority. In most cases, employees must be given back their old job at the end of their pregnancy and/or parental leave.
Cision Canada
4 days ago
- Cision Canada
Canada reaffirms international collaboration with the European Space Agency Français
LONGUEUIL, QC, June 6, 2025 /CNW/ - Today, Sherry Romanado, Parliamentary Secretary to the Minister of National Defence, on behalf of the Honourable Mélanie Joly, Minister of Industry and Minister responsible for the Canadian Space Agency (CSA), joined CSA President Lisa Campbell and the Director General of the European Space Agency (ESA), Dr. Josef Aschbacher, at the John H. Chapman Space Centre (the CSA's headquarters in Longueuil). The two heads of space agencies signed a joint statement reaffirming Canada and ESA's unique, proven and productive partnership. This signature marks a key milestone in the mid-term review of the Canada–ESA Cooperation Agreement. For nearly 50 years, the Canada–ESA Cooperation Agreement has advanced Canadian innovation and expertise on the world stage. Canada's unique status as ESA's only non-European cooperating state gives Canadian companies privileged access to the European space market. Every dollar awarded to Canadian companies through ESA contracts generates nearly three dollars in return, benefitting Canadian businesses and injecting value into the Canadian economy. This collaboration helps Canada's space sector build long-term relationships with the European space community and contributes to strengthening innovation, competitiveness, and technological capabilities. It has propelled numerous Canadian organizations to the forefront of their fields, positioning Canadian expertise at the heart of bold international space missions. Dr. Aschbacher's visit to Canada was a unique and timely opportunity to underscore the deep ties between the space programs of Canada and Europe and to emphasize the shared commitment to fortifying their alliance in order to accelerate and grow their respective space sectors. As Canada looks to strengthen its ties with like-minded countries, including those in Europe, this longstanding partnership provides an opportunity and a proven path for Canada to bolster diversification of the space sector for the benefit of Canadians. Quotes "Today's signature is about reaffirming Canada's long-standing commitment to its collaboration with ESA, which has consistently yielded proven results for our Canadian space sector. As our focus is to unleash a new era of growth for our country, space represents the perfect domain to advance innovation and contributes to our goal of building a stronger Canada." — The Honourable Mélanie Joly, Minister of Industry and Minister responsible for the Canadian Space Agency "With this signature and the creation of the ESA–CSA task force, we are finding even more common synergies between ESA's activities and Canada's own priorities and strengthening the long-standing relationship between Europe and Canada. Canada's status as a non-European ESA cooperating state positions Canadian expertise – and industry – at the heart of bold international space missions. In today's geopolitical and economic environment, strong and reliable partnerships are more important than ever. ESA is proud to partner with Canada, and I look forward to our continued successes together." — Dr. Josef Aschbacher, Director General of the European Space Agency Quick facts Funded by the CSA, the Canada–ESA program allows Canadian organizations access to contracts related to ESA programs. Between January 2018 and December 2024, this collaboration led to 233 ESA-funded contracts to 82 Canadian entities, valued at approximately CAN$192 million. Behind these numbers is a growing network of Canadian talent and technology now woven into ESA's most advanced programs – from space robotics to next-generation communications. Canada and ESA have been collaborating in the space sector since the early 1970s. Formal cooperation began in 1979 with the signing of the first Cooperation Agreement. The Agreement has been renewed five times since (1984, 1989, 2000, 2012 and 2019). Dr. Josef Aschbacher's official visit to Canada took place from June 4 to 6, 2025. It included engagements with senior government officials and industry leaders in Ottawa and Montreal. Links SOURCE Canadian Space Agency
